FULC logo

FULC Fulcrum Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$3.72
-0.03 (-0.80%)

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered feta…

Market Cap: $284.14Mwww.fulcrumtx.com

Price

No data yet.

Social Signal Score

40
5d
—
30d
—
60d
40
5 mentions
—
90d
39
11 mentions
—
news: 11

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 7Sell 3Strong Sell 0
Avg price target$3.6-3.2%
Low $3Median $4High $4
Current Consensus

Revenue

$0.00
$0.00$26.67M$53.33M$80.00M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-1.16
$-1.20–$-1.10
10 analysts
FY2026
$-0.60
$-0.81–$-0.49
5 analysts
FY2027
$-0.12
$-0.26–$-0.04
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Alexander C. Sapir
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
2.77
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
16.91
www.fulcrumtx.com